Combigene AB
A gene therapy company focused on neurological disorders and chronic pain.
COMBI | ST
Overview
Corporate Details
- ISIN(s):
- SE0016101935
- LEI:
- 213800CITFPHX4TL8G93
- Country:
- Sweden
- Address:
- Agavägen 52A, 181 55 Lidingö
- Website:
- https://combigene.com
Description
CombiGene AB is a gene therapy company focused on developing treatments for severe, life-altering diseases with significant unmet medical needs, particularly neurological disorders. The company's lead project, CG01, is an adeno-associated virus (AAV)-based gene therapy candidate designed for the treatment of drug-resistant focal epilepsy. In 2021, CG01 was exclusively licensed in a global agreement to Spark Therapeutics. CombiGene is also developing a gene therapy for chronic pain through a collaboration with the company Zyneyro. The company's mission is to provide patients with the prospect of a better life through novel gene therapies where current treatment methods are inadequate.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Combigene AB filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Combigene AB
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Combigene AB via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
